Siam Bioscience Co Ltd has set up a joint venture firm with the Cuba-based Centre of Molecular Immunology to invest up to 3 billion baht ($86.5 million) on research and development of biopharmaceuticals targeting cancer and auto-immune diseases in Thailand, according to The Nation’s report.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
